Clinical Trials · NCT02532400
Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients
- Phase
- Phase 3
- Recruitment status
- Terminated
- Sponsor
- Ruijin Hospital
- Enrollment
- 21
- Start date
- Mar 2016
- Locations
- 1 site, China
- Primary endpoint
- Overall response rate(ORR)